Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
National Cancer Institute (NCI)
Mayo Clinic
Children's Oncology Group
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
University of Washington
M.D. Anderson Cancer Center
City of Hope Medical Center
City of Hope Medical Center
Mayo Clinic
Emory University
Mayo Clinic
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Mayo Clinic
Mayo Clinic
NRG Oncology
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
University of Kansas Medical Center